Completed PHASE1 INTERVENTIONAL 2-arm NCT03196804

A Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126.

A Dose Blocked-randomized, Double-blind, Placebo-controlled, Multiple Dosing and Dose-escalation Phase I Clinical Trial to Investigate the Safety, Tolerability and Pharmacokinetic Characteristics of LC28-0126 in Healthy Male Subjects

Sponsor: LG Chem

Conditions Healthy

Interventions LC28-0126 Placebo

Updated 7 times since 2017 Last updated: Apr 10, 2018 Started: Jun 7, 2017 Primary completion: Nov 15, 2017 Completion: Nov 15, 2017

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE1 clinical study on Healthy, this trial is completed. The trial is conducted by LG Chem and has accumulated 7 data snapshots since 2017. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Status Flow

Change History

7 versions recorded

Sep 2025 — Present [monthly]

Completed PHASE1
Sep 2024 — Sep 2025 [monthly]

Completed PHASE1
Jul 2024 — Sep 2024 [monthly]

Completed PHASE1
Jan 2021 — Jul 2024 [monthly]

Completed PHASE1
Jun 2018 — Jan 2021 [monthly]

Completed PHASE1

▶ Show 2 earlier versions

May 2018 — Jun 2018 [monthly]

Completed PHASE1

Status: Recruiting → Completed
Aug 2017 — May 2018 [monthly]

Recruiting PHASE1

First recorded

Jun 2017

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

LG Chem

Data source: LG Chem

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Seoul, South Korea